secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K/A
Filed at:   2026-11-09T21:39:21+00:00
Accession:  0001193125-26-453730
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Zymeworks completes Theravance merger; pro forma 9M26 net income $11.8M on $321.2M revenue
--------------------------------------------------------------------------------

- Merger completed Sept 23, 2026: each Theravance share converted into $17.00 cash plus one CVR tied to ampreloxetine proceeds and sales.
- Consideration for shares $887.2M plus $28.4M equity awards; total $915.6M, reduced by $355.2M cash acquired, net $560.4M.
- Financing includes $350M OMERS non-recourse notes at 8.25%, maturing Dec 31, 2036, secured by YUPELRI assets with 75% of YUPELRI profit-share cash flows assigned.
- Pro forma 9M 2026 revenue $321.2M and net income $11.8M ($0.15 diluted EPS); FY2025 pro forma revenue $213.4M and net loss $43.7M ($0.58).
- Preliminary purchase accounting: $415.4M YUPELRI product rights, $96.7M TRELEGY milestone receivable, $104.4M goodwill, $91.6M unrecognized tax benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526453730/0001193125-26-453730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526453730/d79244d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-453730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer